CDNA
CareDx, Inc
CDNA has the edge over OSCR overall, supported by stronger fundamentals and stronger modeled upside.
OSCR
Oscar Health, Inc.
OSCR offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
CDNA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Healthy | |
| Strong |
CDNA's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CDNA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $35.14 | -56% |
| Fair | 18x | $42.70 | -46% |
| Expensive | 24x | $57.27 | -28% |
| Current | 33x | $79.81 | — |
| Forward | 54x | $79.81 | — |
Historical ranges are pointers, not guarantees.
CDNA's PE is in its expensive range at 33x. On analysts' estimates for next year's earnings, today's price would be 54x.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over CDNA in the historical PE scenario, which offers more potential upside but is not a forecast.
CDNA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for CDNA, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over CDNA on the outlook, with more favorable valuation expectations.
CDNA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.48 | -38% |
| Q3 2026 | $2.39 | +117% |
| Q2 2026 | $2.07 | +123% |
| Q1 2026 | -$0.16 | -115% |
| Q4 2025 | -$0.40 | -143% |
| Q3 2025 | $1.10 | +$3.80 |
| Q2 2025 | $0.93 | +$3.92 |
| Q1 2025 | $1.06 | +$4.48 |
| Q4 2024 | $0.93 | +$4.47 |
CDNA has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
CDNA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $139.4M | +39% |
| Q2 2026 | $131.9M | +52% |
| Q1 2026 | $117.7M | +39% |
| Q4 2025 | $108.4M | +25% |
| Q3 2025 | $100.1M | +21% |
| Q2 2025 | $86.7M | -6.1% |
| Q1 2025 | $84.7M | +18% |
| Q4 2024 | $86.6M | +32% |
CDNA's revenue has grown year over year for five quarters in a row: $139M last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +6.1 points |
| Q2 2026 | 86% | +99 points |
| Q1 2026 | 1% | +17 points |
| Q4 2025 | -5.6% | -92 points |
| Q3 2025 | -0.3% | +12 points |
| Q2 2025 | -13% | -8.4 points |
| Q1 2025 | -16% | +11 points |
| Q4 2024 | 86% | +273 points |
CDNA has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CDNA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
CDNA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.1M | -70% |
| Q2 2026 | $28.7M | +191% |
| Q1 2026 | $514K | +$27.1M |
| Q2 2023 | -$499K | +$3.4M |
| Q1 2023 | $671K | +$22.1M |
| Q4 2022 | $7.2M | +72% |
| Q3 2022 | -$7.1M | -$3.8M |
| Q2 2022 | -$3.9M | -156% |
CDNA generated $62M in free cash flow over the past year, about three times what it generated the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CDNA on cash flow, with more consistent year-over-year improvement.
CDNA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.9% | +1.6M shares |
| 1 year | +2.3% | +1.2M shares |
| 3 years | +1.5% | +806K shares |
| 5 years | +4.4% | +2.3M shares |
| Available history | +30% | +12.5M shares |
CDNA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | $12.2M |
| Q3 2025 | $25.6M |
| Q2 2025 | $50M |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CDNA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.9x | Net Cash |
| Q2 2026 | -3.1x | Net Cash |
| Q3 2025 | -1.4x | Net Cash |
| Q2 2025 | -1.3x | Net Cash |
| Q1 2025 | -1.5x | Net Cash |
| Q4 2024 | -2.1x | Net Cash |
CDNA has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over CDNA on leverage, with a lower net debt burden relative to earnings.
CDNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 76.2 | Overbought |
| Stochastic | 81.1 | Overbought |
CDNA's weekly RSI is 76 (overbought) and its Stochastic is 81 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CDNA PE vs Healthcare Sector
| Metric | CDNA | Sector median | Relative |
|---|---|---|---|
| PE | 33x | 26x | 29% above |
| PE % | 97 | 29 | 68 pts above |
CDNA is trading at 33x earnings, a 29% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over CDNA on valuation relative to its sector.
CDNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $71.7 | 11% above |
| 20 week MA | $54.9 | 45% above |
| 50 week MA | $34.1 | 134% above |
| 100 week MA | $25.8 | 209% above |
| 200 week MA | $19.7 | 305% above |
CDNA is in an uptrend: it's above all five of its weekly moving averages, and 305% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
CDNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.5 | $76.2 | +255% |
| 2021 | $76.2 | $44.9 | -41% |
| 2022 | $44.9 | $11.3 | -75% |
| 2023 | $11.3 | $12.0 | +6.6% |
| 2024 | $12.0 | $21.1 | +76% |
| 2025 | $21.1 | $19.5 | -7.6% |
| 2026 YTD | $19.5 | $79.8 | +310% |
CDNA has the edge over OSCR on returns for 2026, with the stronger performance.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to −74% in 2021. It's up 114% so far in 2026.